Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-11-30

Clinical Trial Update: Efficacy and Safety of DWP450 in Subjects With Benign Masseteric Hypertrophy [Phase 3]

View source ↗

Summary

Phase 3 trial updating efficacy and safety of DWP450 for benign masseteric hypertrophy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • DWP450

Snippet

Sponsor: Daewoong Pharmaceutical Co. LTD. | Conditions: Benign Masseteric Hypertrophy | Phase 3 | Status: COMPLETED